The impact of scrambler therapy on pain and quality of life for chemotherapy-induced peripheral neuropathy: A pilot study.

IF 2.5 3区医学 Q2 ANESTHESIOLOGY

Pain Practice Pub Date : 2024-06-01 Epub Date: 2024-02-28 DOI:10.1111/papr.13355

Matthew Chung, Tsun Hsuan Chen, Xin Shelley Wang, Kyung-Hoon Kim, Salahadin Abdi

{"title":"The impact of scrambler therapy on pain and quality of life for chemotherapy-induced peripheral neuropathy: A pilot study.","authors":"Matthew Chung, Tsun Hsuan Chen, Xin Shelley Wang, Kyung-Hoon Kim, Salahadin Abdi","doi":"10.1111/papr.13355","DOIUrl":null,"url":null,"abstract":"Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating disturbance among patients who received chemotherapy, with no effective treatment available. Scrambler therapy (ST) is a noninvasive treatment capable of improving multiple quality-of-life symptoms beyond pain. We aimed to evaluate the efficacy of ST for pain and nonpain symptoms related to CIPN.Methods: Ten patients with moderate to severe CIPN symptoms for >3 months were enrolled in a single-arm trial of ST for 10 daily sessions. CIPN-related symptoms were measured throughout the treatment period and up to 6 months thereafter.Results: The worst pain was reduced by 6 months (p = 0.0039). QST demonstrated the greatest improvement in pressure of 60 g (p = 0.308, Cohen's d = 0.42) and cold temperature threshold of 2.5°C (p = 0.9375, Cohen's d = 0.51) in the gastrocnemius area. Symptoms of numbness, tingling, trouble walking, and disturbed sleep had significant improvements at 6 months. Pain medication use decreased by 70% at the end of treatment and by 42% at 6 months. Patient satisfaction was high (82%) and no adverse events with ST treatment were reported.Conclusions: The results of this pilot trial support the use of ST by demonstrating improvement in multiple domains of quality of life for CIPN patients during an extended follow-up of 6 months. However, further large-scale studies are needed to confirm our findings.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"749-759"},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/papr.13355","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating disturbance among patients who received chemotherapy, with no effective treatment available. Scrambler therapy (ST) is a noninvasive treatment capable of improving multiple quality-of-life symptoms beyond pain. We aimed to evaluate the efficacy of ST for pain and nonpain symptoms related to CIPN.

Methods: Ten patients with moderate to severe CIPN symptoms for >3 months were enrolled in a single-arm trial of ST for 10 daily sessions. CIPN-related symptoms were measured throughout the treatment period and up to 6 months thereafter.

Results: The worst pain was reduced by 6 months (p = 0.0039). QST demonstrated the greatest improvement in pressure of 60 g (p = 0.308, Cohen's d = 0.42) and cold temperature threshold of 2.5°C (p = 0.9375, Cohen's d = 0.51) in the gastrocnemius area. Symptoms of numbness, tingling, trouble walking, and disturbed sleep had significant improvements at 6 months. Pain medication use decreased by 70% at the end of treatment and by 42% at 6 months. Patient satisfaction was high (82%) and no adverse events with ST treatment were reported.

Conclusions: The results of this pilot trial support the use of ST by demonstrating improvement in multiple domains of quality of life for CIPN patients during an extended follow-up of 6 months. However, further large-scale studies are needed to confirm our findings.

查看原文本刊更多论文

扰频疗法对化疗引起的周围神经病变的疼痛和生活质量的影响：试点研究。

背景：化疗引起的周围神经病变（CIPN）是化疗患者的一种衰弱性障碍，目前尚无有效的治疗方法。抗痉挛疗法（ST）是一种非侵入性治疗方法，能够改善疼痛以外的多种生活质量症状。我们旨在评估 ST 对 CIPN 相关疼痛和非疼痛症状的疗效：十名中度至重度 CIPN 症状持续时间超过三个月的患者参加了 ST 的单臂试验，每天 10 次。在整个治疗期间及其后的 6 个月内，对 CIPN 相关症状进行测量：结果：最严重的疼痛在 6 个月后有所减轻（p = 0.0039）。QST 对腓肠肌区域 60 g 压力（p = 0.308，Cohen's d = 0.42）和 2.5°C 冷温阈值（p = 0.9375，Cohen's d = 0.51）的改善最大。麻木、刺痛、行走困难和睡眠障碍等症状在 6 个月后均有明显改善。治疗结束时，疼痛药物的使用减少了 70%，6 个月时减少了 42%。患者满意度很高（82%），ST 治疗未出现不良反应：这项试点试验的结果表明，在延长 6 个月的随访期间，CIPN 患者的多个生活质量领域都有所改善，因此支持使用 ST。然而，还需要进一步的大规模研究来证实我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pain Practice ANESTHESIOLOGY-CLINICAL NEUROLOGY

CiteScore

5.60

自引率

3.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Pain Practice, the official journal of the World Institute of Pain, publishes international multidisciplinary articles on pain and analgesia that provide its readership with up-to-date research, evaluation methods, and techniques for pain management. Special sections including the Consultant’s Corner, Images in Pain Practice, Case Studies from Mayo, Tutorials, and the Evidence-Based Medicine combine to give pain researchers, pain clinicians and pain fellows in training a systematic approach to continuing education in pain medicine. Prior to publication, all articles and reviews undergo peer review by at least two experts in the field.